ARTICLE | Top Story
Alexion reports Phase II CABG data
January 23, 2001 8:00 AM UTC
ALXN said that preliminary results of a Phase IIb study of its pexelizumab C5 inhibitor (5G1.1-SC) showed treatment reduced the composite incidence of death or myocardial infarction (MI) at 30 days by...